ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 931,37
-0,67%
Dow Jones
38 023,96
0,32%
DAX
17 949,40
0,15%
Brent Oil
83,435
-0,13%
Bitcoin
58 306,79
0,12%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Roche Holding Ag (0QQ6)

  7. Roche Holding Ag (0QQ6) Actualités

0QQ6 Roche Holding Ag

229,20
0,00 (0,00%)
Dernière mise à jour : 02:00:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Roche Holding Ag 0QQ6 London Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 229,20 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
229,20
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
24/4/202407:00UKREG[Ad hoc announcement pursuant to Art. 53 LR] Roche sales..
24/4/202407:00UKREG[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der..
19/4/202407:00UKREGFDA approves Roche’s Alecensa as the first adjuvant..
17/4/202408:00UKREGRoche’s subcutaneous OCREVUS one-year data demonstrates..
15/4/202407:00UKREG[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi..
11/4/202407:00UKREGRoche granted FDA Breakthrough Device Designation for blood..
26/3/202417:45UKREGRoche receives FDA approval for the first molecular test to..
12/3/202413:30UKREGRoche Annual General Meeting 2024
12/3/202413:30UKREGAssemblée générale 2024 de Roche
12/3/202413:30UKREGRoche Generalversammlung 2024
05/3/202413:30UKREGRoche and Alnylam report positive topline results from the..
25/2/202420:00UKREGNew England Journal of Medicine publishes Phase III data..
16/2/202417:24UKREGFDA approves Xolair as first and only medicine for children..
01/2/202407:03UKREGNew long-term data for Roche’s Vabysmo show sustained..
01/2/202407:00UKREG[Annonce événementielle au sens de l’art. 53 RC] Roche..
01/2/202407:00UKREG[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds..
01/2/202407:00UKREG[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft..
16/1/202407:00GLOBEEuropean Commission approves Roche’s Tecentriq SC, the EU's..
29/12/202322:30GLOBERoche enters into a definitive agreement to acquire..
19/12/202315:40GLOBEFDA grants priority review to Xolair (omalizumab) for..
15/12/202307:15GLOBERoche named among top three most sustainable healthcare..
11/12/202307:00GLOBENew data for Roche’s Columvi and Lunsumio presented at ASH..
09/12/202317:30GLOBENew data reinforce the benefit of early preventative..
08/12/202317:50GLOBERoche's Kadcyla is the first targeted therapy to show..
08/12/202317:45GLOBERoche’s inavolisib combination reduces the risk of disease..
05/12/202307:00GLOBERoche announces positive Phase III results for inavolisib..
04/12/202307:00GLOBERoche enters into a definitive merger agreement to acquire..
27/11/202307:00GLOBERoche expands hepatitis diagnostics portfolio to help..
16/11/202307:00GLOBERoche launches automated serology hepatitis E virus tests,..
14/11/202307:00GLOBERoche’s subcutaneous injection of Tecentriq recommended by..
09/11/202307:00GLOBERoche’s Elecsys NfL test, an important aid for those living..
30/10/202321:01GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche announces..
27/10/202307:00GLOBE[Ad hoc announcement pursuant to Art. 53 LR] FDA approves..
23/10/202313:18IHMARKETNEWSMonday’s Wall Street Highlights: Philips, Chevron,..
23/10/202307:00GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche enters..
19/10/202307:00GLOBE[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem..
18/10/202307:03GLOBERoche IL-6 is the first immunoassay approved to aid sepsis..
18/10/202307:00GLOBERoche’s Alecensa reduces the risk of disease recurrence or..
13/10/202315:30GLOBELate-breaking data for Roche’s BTK inhibitor fenebrutinib..
12/10/202307:00GLOBENew data for Roche’s OCREVUS show that after 10 years of..
11/10/202308:00GLOBERoche’s OCREVUS twice-yearly, 10-minute subcutaneous..
10/10/202307:00GLOBERoche’s Vabysmo maintained vision improvements with extended..
04/10/202307:00GLOBEMajority of newborn babies with spinal muscular atrophy..
02/10/202307:00GLOBERoche to present new key clinical and real-world data at..
07/9/202313:00GLOBERoche and Alnylam report positive topline results from Phase..
01/9/202307:00GLOBERoche’s Alecensa delivers unprecedented Phase III results..
29/8/202311:00GLOBERoche’s Tecentriq becomes the first subcutaneous..
29/8/202307:00GLOBEEuropean Commission approves Roche’s Evrysdi for babies..
23/8/202307:22GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche provides..
27/7/202307:00GLOBE[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet..

Dernières Valeurs Consultées

LSE
0QQ6
Roche
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés